| SCHEDULE OF ACCRUED EXPENSES |
Accrued expenses consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
March 31,
2024 |
|
|
December 31,
2023 |
|
|
|
|
|
|
|
|
Accrued pre-clinical and clinical costs |
|
$ |
700,430 |
|
|
$ |
1,449,188 |
|
Accrued product development costs |
|
|
1,506,800 |
|
|
|
745,447 |
|
Accrued license costs |
|
|
4,525,000 |
|
|
|
4,825,000 |
|
Accrued compensation |
|
|
800,246 |
|
|
|
2,325,488 |
|
Accrued administrative costs |
|
|
420,008 |
|
|
|
343,285 |
|
Accrued interest |
|
|
1,445,741 |
|
|
|
1,342,098 |
|
Total |
|
$ |
9,398,225 |
|
|
$ |
11,030,506 |
|
|